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THE ROLE OF ERBB3 INHIBITORS AS CANCER THERAPEUTICS 
ANKUSH CHANDRA 
 
 
 
ABSTRACT 
 
Cancer is the most fatal disease after cardiovascular disease with over 8.2 million deaths 
worldwide each year. Ever since the serendipitous discovery of mustard gas as an anti-
cancer therapeutic in the 1940s, serious efforts have been put into discovering more 
chemotherapies. Chemotherapies can be categorized into different groups such as 
alkylating agents (cisplatin, cyclophosphamide), antimetabolites (5-fluorouracil, Ara-C) 
and mitotic inhibitors (taxanes, vinca alkoids) among others. While chemotherapies have 
proven to kill cancer cells by targeting cell division processes, over time, tumor cells can 
adapt and become resistant to these drugs. With a growing understanding of cell signaling 
networks, targeted therapies are being developed to overcome the issue of chemotherapy 
resistance.  Targeted therapies are highly specific molecules that bind to a specific 
cellular protein or molecule and block signaling networks associated with biological 
processes. One of the most frequently dysregulated receptor systems in cancers is the 
receptor tyrosine kinase family with ErbB being one of the most studied receptors 
families.  
ErbB or HER receptors consists of four structurally related receptor tyrosine 
kinases namely, EGFR/ErbB1, HER2/ErbB2, HER3/ErbB3 and HER4/ErbB4. The ErbB 
family of receptors plays a major role in morphogenesis of the human body as well as 
various cellular responses such as cell growth, differentiation and proliferation. 
 v 
Overexpression and dysregulation of these receptors, particularly EGFR and HER2, have 
been linked to a number of cancers such as breast cancer, gastric cancer, ovarian cancer 
and non-small cell lung cancer, to name a few. One of the most successful therapies 
against ErbB related cancers have been targeted therapies. Targeted therapies for ErbB 
related cancers are of two kinds: (i) Small molecule tyrosine kinase inhibitors (such as 
erlotinib and gefitinib against EGFR) and, (ii) Monoclonal antibodies (such as 
trastuzumab against HER2 and cetuximab against EGFR). These drugs function either by 
inhibiting the kinase activity of the receptor and preventing phosophorylation of tyrosine 
residues, or binding to some other site on the extracellular domain of the receptor and 
preventing ligand binding and heterodimerization of ErbB monomers. These drugs have 
proven to have limited efficacy as monotherapy, but are more effective in combination 
with standard chemotherapies. However, tumor cells can adapt their signaling networks 
developing resistance to targeted therapies over the course of treatment and lead to cancer 
progression. 
 While overexpression and dysfunction of EGFR and HER2 are implicated in most 
ErbB driven cancers, recent studies have found HER3 playing a pivotal role in inducing 
resistance to EGFR and HER2 targeted therapies in various cancers and has been found 
to be the most sensitive node in driving the PI3K pathway leading to tumorigenesis. 
Thus, there is an urgent need to develop drugs targeted against HER3 and bring them into 
the clinic. Since HER3 lacks kinase activity, only monoclonal antibodies can be 
developed against it. Currently, there are a number of molecules in clinical development 
that target HER3. For example, patritumab and MM-121 are humanized monoclonal 
 vi 
antibodies that target the extracellular domain of HER3 receptor and leads to inhibition of 
HER3-PI3K signaling followed by rapid internalization of the receptor. MM-111 and 
MM-141, two different bispecific monoclonal antibodies that bind to HER2, HER3 and 
IGFR-1, HER3, respectively, are currently in clinical development.  
 HER3 inhibitors provide hope to effectively overcome HER3 induced tumor 
resistance and successfully treat several ErbB driven cancers. However, further 
development of HER3 inhibitors is necessary by taking strategic approaches. One of 
these approaches it the utilization of systems biology, a branch of biology that involves 
computational and mathematical modeling of complex biological systems with the aim of 
discovering emergent properties of biological systems. Systems biology enables 
researchers to get a deeper understanding of biological networks such as that of ErbB and 
make predictive models and test outcomes. This approach was used by Merrimack 
Pharmaceuticals to develop novel monoclonal antibodies against HER3. Computational 
outcomes were successfully validated by in vitro and in vivo experiments. Thus, this 
suggests that systems biology might be the future of designing and developing HER3 
inhibitors that would successfully overcome HER3 resistance and cancer progression. 
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INTRODUCTION 
 
 
Cancer, as defined by the World Health Organization (WHO), is a term used for a 
large number of diseases characteristic of abnormal growth beyond a cell’s usual cell 
division capability. These cells can metastasize or invade other parts of the body, even far 
away from the primary source and can cause death
1
.   
Based on a report by the WHO and CDC, cancer caused 8.2 million deaths in 2012 
worldwide, making it the second most fatal disease in the US (Figure 1) and worldwide 
falling just behind cardiovascular diseases
2
.  
 
Figure 1: Leading causes of death in 2010 
Cancer caused the second most deaths in the U.S with 574,743 fatalities. 
Figure taken from CDC Morbidity and Mortality Weekly Report 2010(3).
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Causes of this deadly disease can be attributed to environmental and genetic factors.  
Environmental factors can be split into 3 categories: (i) Chemical carcinogens (ii) 
Physical carcinogens, and (iii) Infectious agents. Chemical carcinogens often include agents 
that damage DNA via electrophilic attack on the tissue nucleophile such as coal tar and 
tobacco.  
Physical carcinogens generally include UV radiation, X-rays and other ionizing 
radiations
4
. These carcinogens cause physical damage to the DNA and interferes with the 
DNA replication process. This can lead to mutations potentially leading to carcinogenesis 
4
. 
Last of the environmental factors are infectious agents that include viruses such as 
Human papilloma virus (HPV) that is associated with cervical cancer; bacteria such as 
Helicobacter pylori associated with stomach cancer and other microorganisms
5
. 
On the other hand, genetic factors that cause cancer involve two types of mutations 
(i) inherited, and (ii) somatic mutations. Inherited mutations are those mutations that are 
present in the genetic material of the egg or sperm that lead to the formation of the child and 
is passed on from one generation to another
6
. This is often also known as Family Cancer 
Syndrome such as in the case of hereditary breast and ovarian cancer (HBOC) due to 
mutations in BRCA1 and BRCA2 genes 
4,6
. 
Somatic mutations are those mutations that are acquired over the course of a 
lifespan. Thus, the mutated cell passes on the mutations only to its daughter cells 
5
.  
Whether mutations are inherited or somatic, it is well understood that cancer is 
caused as a result of alteration in genes that are responsible for cell growth regulation, 
differentiation and DNA repair
8
. Such genes are often classified into two groups, (i) tumor 
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suppressor genes: genes that are responsible for limiting cell division and survival, and (ii) 
oncogenes: genes that are responsible for normal cell growth and differentiation. 
Different type of mutations in either of these genes can lead to malignant 
transformations such as an inactivation or under expression of tumor suppressor genes, or 
overexpression or activation mutation of oncogenes
7
. These mutations give a growth or pro-
survival advantage to the cells and could lead to malignancies
8
. 
Oncogenes can also be classified into several categories such as transcription factors, 
chromatin remodelers, signal transducers, apoptosis regulators, growth factors, and growth 
factor receptors
8
.  Of the oncogenes listed above, the last two oncogenes, growth factors and 
growth factor receptors, are of special interest because of their close connection with one 
another and their role in cell growth and tumorigenesis.  
 
GROWTH FACTORS AND GROWTH FACTOR RECEPTORS 
Growth factors, typically proteins or steroids, are molecules produced by cells to 
modulate growth, proliferation and differentiation on neighboring cells (paracrine) or on the 
cell itself (autocrine). They may positively or negatively modulate the cell growth and 
proliferation and play a pivotal role in overall development of the body
17
. Growth factors are 
ligands for growth factor receptors, which on binding lead to downstream activation of 
intracellular signaling cascades further leading to activation or inactivation of certain genes 
which modulate growth and differentiation 
17
. Constitutive activation of growth factor genes 
that are positive modulators of cell differentiation and proliferation can lead to malignancies 
as seen in the case of platelet derived growth factor (PDGF)
 6
. PDGF, secreted by platelets 
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during coagulations, stimulates proliferation of various cell types and fibroblasts during 
wound healing
6
. In vitro studies have indicated that excess PDGF can lead to fibroblast 
transformation leading to uncontrolled cell growth and may cause malignant transformations 
in humans as well. Furthermore, an antibody against PDGF, its receptor or small molecule 
antagonist blocking the receptor prevents the fibroblast transformation confirming the 
hypothesis in in vitro models. 
The primary drivers of growth factors are growth factor receptors and these receptors 
are altered in several types of cancers. Certain families of these receptors are related to 
tumor cell resistance, which is a major topic of therapeutic concern today.  
Growth factor receptors are typically receptor tyrosine kinases (RTKs), which are a 
large family of membrane spanning receptors with intrinsic tyrosine kinase activity that 
share a similar structure: an extracellular ligand binding domain, a cytoplasmic single 
transmembrane domain, and an intracellular tyrosine kinase domain
18
. The ligand-binding 
domain is connected to the cytoplasmic domain by a single transmembrane helix as shown 
in Figure 2 
19, 20
. 
To date, there are about 20 different families of RTKs identified which include  
Epidermal Growth Factor receptors (EGFR/ErbB/HER), fibroblast growth factor receptors 
(FGFR) and  vascular endothelial growth factor receptors (VEGFR) as seen in Figure 2. 
While the RTKs are essential for growth and proliferation of cells, mutations and 
deregulation of these receptors are implications seen in different cancers. 
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Figure 2: Family of RTK along with the 2 different domains. 
There are about 20 families of RTKs discovered till date. Some of them are represented in the figure above. 
Legend EGFR, epidermal growth factor receptor; IR, insulin receptor; PDGFR, platelet-derived growth factor 
receptor; FGFR, fibroblast growth factor receptor; VEGFR, vascular endothelial growth factor receptor; 
HGFR, hepatocyte growth factor receptor; TRK, tropomyosin receptor kinase; AXL, anexelekto (Greek word 
for uncontrolled); LTK, leukocyte tyrosine kinase; TIE, tyrosine kinase with Ig and EGF homology domains; 
DDR, discoidin domain receptor; RET, rearranged during transformation; KLG, kinase-like gene; RYK, 
related to tyrosine kinase; MuSK, muscle-specific receptor tyrosine kinase. Other abbreviations: Cad, cadherin 
repeat; Cys, cysteine-rich region; Discoidin, discoidin or factor VIII domain; EGF, EGF-like repeat; 
Extracellular, extracellular domain; Fn, fibronectin III repeat; Ig, immunoglobulin-like domain; Kinase, 
tyrosine kinase domain; Kringle, kringle domain; L, leucine-rich motif; SS, disulfide bond; TM, 
transmembrane domain. Figure taken from Robertson, et al. 2000(23).  
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ACTIVATION OF RTKs AND DOWNSTREAM SIGNAL TRANSDUCTION 
With the exception of the insulin receptor family, all other known RTKs exist as 
monomers in the cell membrane. Ligand binding leads to the induction of dimerization of 
the receptors that further results in autophosphorylation of trans tyrosine residues in the 
cytoplasmic domain 
21-23
. This is the activated state of the RTK. The phosphorylation of the 
tyrosine residues leads to a conformational change in the receptor and stabilizes the active 
state of the receptor 
25
. 
The phosphotyrosine residues of the receptor become the binding sites for other 
downstream signaling proteins such as adaptor proteins and enzymes, usually, through the 
Src homology-2 (SH2) and/or phosphotyrosine binding domains (PTB) as seen in Figure 3 
below. RTK signaling pathways, as seen in figure 4 will be discussed later in the context of 
ErbB receptors. 
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Figure 3: Mechanism of RTK activation 
Ligand binding on RTKs leads to dimerization of receptors and trans auto-phosphorylation of tyrosine leading 
to activation of RTKs. Figure taken from http://yxsj.baiduyy.com/whole/image/chapter15/15.22.jpg 
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Figure 4: RTK activation in the context of EGFR and downstream pathways 
Ligand binding to EGFR leads to dimerization, trans phosphorylation of tyrosine residues and 
activation of different downstream signaling pathways. Figure taken from 
http://www.genebiomarkers.com/gbm_images/content/egf_pathway.jpg 
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RTKs AND CANCER 
 
RTKs as oncogenes are known to play a role in cancer and tumorigenesis as a result 
of their aberrant signaling
33
. Figure 3 and 4 shows mechanism of activation of RTK 
signaling pathway and signaling pathways associated with RTK activation.  
Constitutive activation of RTK is important for malignant transformations and can 
occur due to a number of mechanisms such as mutations causing constitutive kinase 
activation, overexpression of ligand or RTK receptor and, mutations in the regular signal 
transduction pathways 
34
. However, in most cases, gene amplification, overexpression and 
mutations are responsible for transformation of RTKs.
28 
Several families of RTKs are also associated with cancers. Table 1 summarizes the 
RTK family and the cancer associated with it
28
. 
Table 1: Example of some RTKs associated with different cancers 
RTK family Type of Cancers 
Platelet derived growth factor receptors 
 (PDGFR) 
Glioblastoma, astrocytic brain tumors, 
gastrointestinal tumors 
Vascular Epithelium Growth Factor receptors 
(VEGFR) 
Non-small cell lung cancer, colorectal cancer,  
breast cancer 
 
Epidermal Growth Factor Receptors 
(EGFR/HER) 
Non-small cell lung cancer, cervical cancer,  
bladder cancer, ovarian cancer, kidney cancer, 
pancreatic cancer, squamous cell carcinomas  
of the head and neck, 
Hepatocyte Growth Factor Receptor 
(HGFR/c-MET) 
Colorectal carcinomas, thyroid carcinomas,  
breast cancer, childhood hepatocellular  
carcinoma, non-small lung cancer 
 
Epidermal growth factor receptors (EGFR) or ErbB/HER family of receptors are 
essential for many normal morphogenic processes and are involved in various cellular 
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responses such as cell growth, differentiation and proliferation. Aberrant signaling and 
mutations in this family of receptors can lead to development of tumors in the body, 
primarily, epithelial based cancers
29
. An interesting finding of ErbB driven cancers is 
resistance to traditional chemotherapies. Over the last two decades several drugs have been 
developed to overcome cancer resistance induced by ErbB family of receptors. While these 
drugs have proven to be effective, in the long run the tumor develops resistance and thus 
proving anti-cancer drugs to be ineffective in the long run. This poses a great challenge in 
the clinic and thus there is a dire need to understand mechanisms of resistance more closely 
and develop drugs targeting the cancer cells’ resistance to anti-cancer therapeutics.  
 11 
EGFR/ERBB FAMILY OF RECEPTORS 
The ErbB family of RTKs lies at the head of a complex signal transduction cascade 
that modulates cell proliferation, survival, adhesion and differentiation
29
. The ErbB family 
consists of four members: EGFR/ErbB1, ErbB2/HER2, ErbB3/HER3 and ErbB4/HER4. 
These transmembrane receptors all share two extracellular cysteine-rich domains and an 
intracellular portion with a long C-terminal tail carrying most of the autophosphorylation 
sites (Figure 5). It is interesting to note is that all but HER3 have intrinsic kinase activity in 
the cytoplasmic domain of the receptor and that HER2 has no ligands
30
. These 
characteristics have implications in cancer as discussed later. 
Figure 5: ErbB family of receptors and their ligands 
Some of the possible heterodimers are shown above in the figure. No ligand has been identified for HER2. 
Also, HER3 does not have intrinsic kinase activity. Figure taken from 
http://www.slideshare.net/vj2510/tyrosine-kinase-inhibitors 
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ErbB receptors activate by forming homo and heterodimeric receptor complexes on 
binding of one of the 11 ligands for the family on the extracellular ligand-binding domain
 
(Figure 5)
29
. Ligand binding leads to trans autophosphorylation of tyrosine residues in the 
cytoplasmic domain, which leads to conformational changes in the receptor structure and 
thus stabilize the active state of the kinase. The phosphorylated tyrosines become docking 
sites for signaling complexes such as enzymes and adaptor proteins. Dissociation of these 
complexes releases activated effector and adaptor proteins into the cytoplasm where they 
stimulate different signal transduction cascades such as the mitogen-activated protein kinase 
(MAPK), Akt and phophoinisitol kinase pathways
 
(Figure 6)
36
. 
Figure 6: ErbB signaling network in response to ligands 
ErbB signaling network is highly complex and consists of several layers. The input layer contains receptors 
and ligands, while multiple hidden layers of enzymes, adaptor proteins, second messengers and 
transcription factors lie beneath the cell surface. The output layer includes a variety of cellular responses. In 
most cases, the end result of EGFR activation is stimulation of cell growth. 1, EGFR; 2, HER2; 3, HER3; 4, 
HER4; LPA, lysophosphatidic acid; ET, endothelin. Figure taken from Yarden, et al. 2001(34).  
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Inactivation of ErbB receptors occurs primarily by the activity of protein tyrosine 
phosphatases, while clathrin-mediated endocytosis of receptor-ligand complexes plays a 
secondary role in inactivation and a primary one in receptor internatilization
37,136
. The 
contents of the resulting endosomes following endocytosis can have two fates: (i) 
degradation in the lysosome and, (ii) recycling to the surface of the cell (Figure 7) 
37
. 
 
Figure 7: ErbB family signaling model 
ErbB receptors are activated by ligand binding that causes dimerization of the receptor and cross 
phosphorylation of tyrosine residues. Inactive effector proteins bind to the phosphorylated tyrosines and 
dissociate as activated proteins and activate downstream signaling cascade. Signal is terminated once the 
receptors are endocytosed and then are either degraded in lysosomes or recycled back to the membrane. 
Figure taken from Yarden Y. 2001(147). 
 
HER2 is the preferred dimerization partner for all the other receptors in the 
family. Several mechanisms contribute to HER2 heterodimeric signals potency 
31,32
. First, 
activated heterodimeric complexes including HER2 as one of the monomers are found to 
be more stable at the cell surface than those without HER2
39
. Secondly, while HER2 does 
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not bind a ligand, it can decrease the rate of dissociation of ligand from the associated 
ErbB receptor, thereby, increasing the rate and strength of ErbB signaling network
40
. 
Third, ErbB heterodimers with HER2 as one of the monomers tend to stay much longer 
on the cell surface than those dimers without HER2. Furthermore, once activated dimers 
are internalized into the cell, HER2-EGFR heterodimers are targeted for recycling while 
other heterodimers are targeted for degradation. Thus, HER2 is recycled back to the 
surface for the next round of activation and downstream signaling
39
. Lastly, it is 
important to note that HER2-HER3 heterodimers are the most potent as they directly 
activate the PI3K pathway along with the MAPK pathway
137
. 
Implications in Cancer 
Over the past couple of decades, it has become clear that members of the ErbB 
family play a significant role in initiation and maintenance of many solid tumors (Table 2). 
Several mutations and overexpression of these receptors play a major role in tumorigenesis. 
The EGF Receptor 
 
Originally identified as an oncogene because of its homology to v-ERBB, EGFR is 
mutated or overexpressed in several cancers as seen in Table 2
29
.  Several single residue 
mutations in the EGFR extracellular region have been reported in different types of cancers, 
especially glioblastoma
43
. 
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Table 2: Cancer types associated with different ErbB receptor types and alterations.* 
*Adapted from Arteaga, C. L., et al. 2014(44).  
 
One of the most studied EGFR mutation found in ~40% of high grade gliomas with 
wild type EGFR amplification is variant III (vIII), which lacks residues 6-273 in the 
extracellular region of the wild type receptor
28,47
. Studies have indicated that EGFRvIII has 
constitutive dimerization, aberrant tyrosine kinase activity and impaired downregulation
 
and 
thus results in enhanced tumorigenecity
44,45,48
.  Moreover, in addition to glioblastoma, 
EGFRvIII has also been found in a fraction of lung, breast, head and neck, ovarian and 
prostate cancers
49
.  
The second most common EGFR variant or mutant, found in ~20% of glioblastoma 
cases with wild type EGFR amplification, is EGFRc958. This variant lacks amino acids 
521-603 and exhibits increased ligand dependent kinase activity
50. 
 
Apart from mutations, overexpression of EGFR is another mechanism of 
tumorigenecity frequently found in several cancers such as that of the cervix, bladder, ovary, 
kidney, pancreas and head and neck (Table 2). The primary mechanism of EGFR 
Molecule Alteration Cancer Types 
EGFR Mutation NSCLC (Adenocarcinoma) 
EGFR vIII glioma 
EGFR Amplification NSCLC (squamous), head  
and neck, glioma, esophageal, 
colorectal 
HER2 Amplification Breast, gastric, esophageal 
HER2 Mutation Breast(lobular), lung, gastric, 
bladder, endometrial 
HER3 Mutation  Breast, gastric, colorectal 
cancer and NSCLC 
HER4 Mutation  Melanoma, NSCLC, 
medulloablastoma 
 16 
overexpression was found to be amplification of the EGFR gene with more than 15 copies 
per cell reported in several tumors
52
. 
HER2 receptor 
 
In year 1984, Schechter and colleagues found the first evidence of ErbB2/HER2 in 
cancer. HER-2 positive breast cancer, in which overexpression or gene amplification of 
HER2 occurs, accounts for 20-30% of all breast cancer subtypes and has the second-poorest 
prognosis among breast cancer types as well as is correlated with much lower disease free 
and survival rates
46
.  
Typically, HER2 is expressed at low levels on the surface of epithelial cells and is 
essential for normal development of tissues such as those of the breast, lungs, liver, kidney 
and nervous system
47
. However, in HER2+ breast cancer cells, immunohistochemical 
imaging has shown number of receptors in the upwards of 2 million per cell in contrast to 
HER2+ normal cells such as cardio myocytes with less than 20,000 receptors/cell
45,46,146
.  
As mentioned earlier in the ErbB chapter, HER2 is the preferred ErbB partner for 
heterodimer formation and its signaling is the most potent. Thus, with an overexpression of 
HER2 receptors on the cell surface, there is increased availability for heterodimer formation. 
This subsequently leads to prolonged activation of several downstream pathways, 
specifically mitogenic pathways, and leads to abnormal growth and tumorigenecity (Figure 
8). In addition, HER2 amplification is also seen in gastric and esophageal cancer as well and 
causes tumorigenecity by a similar mechanism as that in HER2+ breast cancer discussed 
above
100
. 
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HER2 has become a prognostic and predictive biomarker for a number of cancers, 
especially, for breast cancer. In 1987, Slamon et al. found a strong correlation between 
HER2 overexpression and reduced survival of breast cancer patients
44
.  Furthermore, Yu 
and Hung extrapolated from clinical and laboratory data that overexpression of HER2 
increases the metastatic potential of human lung and breast cancer thereby indicating that 
HER2 overexpression status can also give insight into tumor progression and its response to 
chemotherapies
53
. In addition, studies performed by Houston et al. found that HER2 
expression leads to lack of response of breast tumor to anti-estrogen therapy and leads to 
resistance to tamoxifen
54
. 
 
 
 
 
 
 
 
 
 
 
Figure 8: Signaling pathways associated with HER2 activation. 
Post activation of HER2 receptors, downstream signaling cascade gets activated and can activate different 
pathways such as PI3K-Akt pathways, MEK/ERK pathway or MEK/JNK pathways that lead to evasion of 
apoptosis, cell proliferation and tumor management. Figure taken from Vu and Claret, 2012(49). 
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HER3 Receptor 
 ErbB3 or HER3 was first discovered and isolated from human mammary tumor cell 
lines in 1989 by Dr. M.H. Kraus
60
. Because it has very low intrinsic kinase activity, HER3 
was believed to be dependent on other HER receptors for its activation and thus its clinical 
relevance was considered insignificant until recently
56
. Recent studies have shown that 
HER3 is involved in tumorigenesis, cancer progression and chemotherapeutic resistance in 
several types of cancers
55.  This has been attributed to HER3’s ability to directly bind to 
PI3K without the need of any adaptor proteins and activate the PI3K pathway
137
. 
To truly understand the distinctive properties of HER3 and its role in cancer, it is 
important to delve into its structure, mechanism of activation and signal transduction 
pathways associated with it. 
Structure of HER3 
 Structurally, HER3 is very similar to the other HER receptors with an extracellular 
domain, transmembrane helix domain and intracellular tyrosine kinase domain
 
(Figure 9)
56
. 
However several structural differences give HER3 its distinctive properties. First, the 
extracellular domain has 2 specific ligand-binding regions (district I and III) and 2 cysteine-
rich regions (district II and IV). The interaction between the two cysteine rich regions 
provides a structural bias for conformational change of HER3 on ligand binding
57
. Second, 
while the transmembrane domain shares significant homology with other HER receptor 
structures, many important structural differences are found in the intracellular kinase 
domain that make HER3 distinctive. The intracellular domain is divided into three: the 
juxtamembrane region (JM), a kinase domain and the C-terminal tail. The JM region is 
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further divided into 2, namely, JM-A and JM-B and the kinase domain is divided into N-
lobe, helix αC, activation loop and C-lobe.  JM-A region interacts with other HER receptors 
while JM-B region binds to the C-lobe and forms a stabilizing latch
58
. C-lobe combines with 
and activates other HER receptors, conferring the properties of a functional activator to 
HER3. In addition, conformational changes in helix αC, responsible for anchoring activator 
kinase domain to recipient kinase domain, are important for HER3 functioning. For 
instance, Thr738 in helix αC of HER3 replaces Leu736 in helix αC of EGFR and stabilizes 
the inactivation state of HER3
59
.  
  Some other important structural differences include 14 tyrosine residues in the 
HER3 C-terminal tail, which include six PI3K binding sites. These binding sites mediate 
interactions between three regulatory subunits of PI3K, specifically SH2 domains of p85. 
This interaction leads to allosteric activation of p110, the lipid kinase subunit of PI3K and 
causes activation of downstream signaling of the PI3K/Akt pathway
59-61
. Lastly, HER3 lacks 
several key residues required for catalytic activity such as the lack of Asp813, which is 
present in EGFR.  
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Figure 9: Structure of HER3 receptor 
HER3 receptor consists of an extracellular ligand binding domain, a transmembrane helix domain and an 
intracellular TKD. The intracellular region is divided into a juxtamembrane region, a kinase domain and C-
terminal tail. The juxtamembrane region is divided into JM-A and JM-B. The kinase domain includes N-
lobe, helix αC, activation loop and C-lobe. HER-3, human epidermal growth factor receptor-3; TKD, 
tyrosine kinase domain. JM-A, juxtamembrane-A; JM-B, juxtamembrane-B. Adapted from Li, Q. et al. 
2013(53).  
 
Thus, as a result it was believed by the scientific community that HER3 does not 
have tyrosine kinase activity and catalytic activity
62,63
. However, studies by Kornev and 
Taylor in 2009 proved otherwise and showed that HER3 exhibits intrinsic tyrosine kinase 
activity, albeit very low, in comparison to other HER receptors. Further, Jura et al showed in 
2009 that HER3 acted as a specific allosteric activator for recipient protein kinases from 
other receptors within the family. 
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Dimerization and Activation 
HER3 functions by forming dimers just like other HER receptors. On ligand binding, 
HER3 changes conformation and thus forms homo or heterodimers. Dimerization of HER3 
switches it from inactive state to active state and leads to tyrosine kinase activity and 
activation of downstream signaling pathways associated with it
66
. HER3 dimerizes with 
other HER family receptors, but in particular two heterodimeric combinations are significant 
in cancer. First, HER3 directly interacts with EGFR when EGF binds to EGFR, its ligand. 
EGFR, on activation with EGF, can cross activate HER3 simultaneously and lead to 
activation of downstream signaling pathways. This was confirmed by using tyrosine kinase 
inhibitors (TKI) that inhibited downstream signaling pathways as a result of blocking EGFR 
and HER3 interactions 
67
.  
Secondly, HER3 interacts directly with HER2. In fact, it is the most preferred 
dimerization partner for HER3 and mainly interacts with HER2. Since HER3 has very low 
catalytic activity, it depends on HER2 for signaling, while HER2, a ligand-less receptor, 
functions in the context of heterodimerization with HER3. For this interaction to occur it is 
necessary for heregulin (HRG), ligand for HER3, to bind the extracellular domain of HER3. 
On binding, HRG causes a conformation change in the extracellular domain of HER3, 
releasing a locked conformation and extending the dimerization loop
62
. Thus the 
dimerization loop latches onto the predisposed dimerization loop of HER2 and forms an 
active heterodimer (Figure 10A).  A second mechanism for HER2-HER3 dimerization has 
been proposed in the context of HER2 overexpression while in the absence of a ligand.  
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Overexpression of HER2 on the cell surface may lead to spontaneous heterodimer 
formation with HER3 even in the absence of a ligand (Figure 10B). This interaction leads to 
a ligand induced conformation and results in a weak yet prolonged receptor activation
62
. 
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Figure 10: Mechanisms of HER3 receptor heterodimerization. 
(A)The extracellular domain of HER3 binds to the dumbbell shaped HRG or NRG. On binding to the 
ligand, the dimerization loop is exposed and it interacts with the dimerization loop of HER2. This forms an 
active heterodimer.(B) HER2 overexpression leads to ligandless dimerization with HER3. The dimers may 
assume a ligand induced conformation and leads to weak but prolonged receptor activation.  Taken from 
Citri A et al. 2003(60). 
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Downstream signaling pathway associated with HER3: MAPK and PI3K/PDK/Akt 
 There are two relevant signaling pathways that are associated with HER3: (i) 
Mitogen activated protein kinase (MAPK) pathway, and (ii) Phosphatidylinositol 3-kinase 
(PI3K)/3-phosphoinositide-dependant protein kinase (PDK) 1/protein kinase B (Akt) 
pathway
55,62
.  
MAPK signaling pathway, responsible for cell proliferation, is activated when there 
is ligand-induced activation of the HER3 heterodimer, which binds Grb2 through a 
phosphorylated tyrosine-based consensus site, or indirectly through interaction with SHC
65
. 
Grb2 associates with Sos, which in turn activates Ras, a GTPase. Ras-GTP leads to 
activation of a linear cascade involving activation of Raf, MEK and finally MAPK (Figure 
11)
55, 62
. 
The PI3K pathway, on the other hand, regulates cell growth, apoptosis, tumor cell 
invasion, metastasis and even chemotherapy resistance in tumor cells
62
. This pathway is 
stimulated by formation of heterodimers between HER3 and EGFR/HER2. PI3K is a 
dimeric protein kinase that consists of a regulatory subunit, p85, and a catalytic subunit, 
p110
64
. Binding of p85 to the phosphotyrosine consensus site of the receptor leads to 
allosteric activation of p110. p110 then phosphorylates phosphophatidylinositol 4,5-
bisphosphate (PIP2) to phosphophatidylinositol 3,4,5-triphosphate (PIP3) which can be 
cleaved by 5’-inositol phosphatases to phosphophatidylinositol 3,4,-triphosphate69. Upon 
production of PIP3 and phosphophatidylinositol 3,4,-triphosphate following PI3K 
activation, Akt is recruited to the plasma membrane by its PH domain and is phosphorylated 
by PDK1. Phosphorylation of Akt leads to its activation and it translocates into the nucleus 
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and leads to regulation of apoptosis or cell growth
68,69
. PTEN, a tumor suppressor and a lipid 
phosphatase is a molecule that is responsible to turn of this pathway. It basically 
dephosphorylates phosphophatidylinositol 3,4,-triphosphate and PIP3, thereby 
downregulating the activity of PDK and Akt
62,69
. Figure 11 illustrates the signaling 
pathways associated with HER3. 
 
Figure 11: HER3 related signaling pathways and the physiological effects on cells 
HER3 can lead to activation of both, MAPK and PI3K/PDK/Akt, pathways following heterodimer 
formation. Taken from Citri A et al. 2003(60). 
 
 
HER3 and Cancer 
 
The clinical significance of HER3 was not considered until recently, although, it 
was found to be overexpressed in several cancers such as breast cancer and colorectal 
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cancer. In 2009, Schoeberl et al. found, HER3 to be the most sensitive node in the 
network for AKT phosphorylation when stimulated with HRG or Betacellulin (BTC)
124
.  
This was determined by sensitivity analysis, a computational technique that was used to 
identify key proteins that control the ErbB receptor network in response to ligand 
stimulation (HRG and BTC) using Akt activation as readout
124
.  
Furthermore, by using a systems biology approach, Schoeberl et al. screened and 
developed an antibody that would effectively bind to HER3 on cells with low nanomolar 
affinity and inhibit downstream signaling pathways
124
. Systems biology is the 
computational and mathematical modeling of complex biological systems. This biology-
based interdisciplinary field focuses on complex interactions using a holistic approach to 
biological and biomedical research. The aim of systems biology is to model and discover 
emergent properties of cells, tissues and organisms functioning as a system. These 
typically involve metabolic networks or cell signaling networks
134
. By using this 
approach, MM-121 (now called seribantumab) was developed and has been discussed in 
detail in later sections. 
While overexpression, constitutive activation or mutation of HER3 alone is 
nonmitogenic, its expression with HER2 and HRG not only transmits potent mitogenic 
signals, but also leads to tumorigenesis in several types of cancers
55, 70
. Recent studies 
have shown that HER3 plays a pivotal role in occurrence and progression of lung cancer, 
breast cancer, colorectal cancer and many other cancers
70-72
.  Additionally, HER3 plays a 
critical role in cancer cell resistance to chemotherapeutics and targeted therapies. HER3 
provides an alternative path for cell proliferation, cancer progression and thereby 
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provides an escape mechanism from treatment for cancer cells. More on this will be 
discussed in the next chapter. 
In NSCLC cell lines, overexpression of HER3 accelerated cell growth and 
metastasis of tumor cells. This was further confirmed by performing in vivo studies in 
which downregulation of HER3 inhibited migration of tumor cells, tumor growth as well 
as metastasis
70
. Furthermore, siRNAs to HER3 or its downstream signaling partner 
AKT2 led to suppression of cell growth of lung adenocarcinoma cells in culture
74
. These 
results indicate that lung cancer progression is dependent on HER3 expression and/or its 
downstream signaling pathway. 
 In breast cancer with HER2 gene amplification, HER3 is required for HER2 
induced preneoplastic changes to breast tumor formation
55,75
.  HER3 forms heterodimers 
with HER2 and triggers downstream signaling pathways and breast cancer cell 
proliferation. In fact, studies showed that deletion of HER3 in HER2+ breast cancer cell 
lines produces strong anti-proliferative effects
76
. This is because HER2/HER3 
heterodimers are found to be the most potent of HER heterodimers. 
While there is almost no expression of HER3 in the normal colon, 50-89% of 
colorectal cancer cases have expression of HER3 receptors
77
. Furthermore, in liver cancer 
metastasized from colon cancer, HRG expression is seen in the cancer cells and 
knockdown of HER3 by siRNA significantly reduced HRG-induced migration and 
metastasis of cancer cells from the colon to the liver in vivo. Moreover, increase 
phosphoAkt (pAkt) was found in these cells prior to silencing and PI3K inhibitors had a 
similar effect on the cells as that of knocking down HER3. These findings not only 
 28 
confirm the role of HER3 in progression and metastasis of colorectal cancer, but also the 
involvement of HRG/HER3/PI3K/Akt pathway
78
.  
 Because of the significant involvement of HER3 in tumor dynamics, it has 
become a new therapeutic target with the hopes of developing effective targeted drugs to 
not only treat HER3 driven cancers, but also overcome HER3-induced tumor resistance. 
 
ERBB3 INHIBITORS AS CANCER THERAPEUTICS 
 
 While today the importance of HER3 as a critical node in cancer is understood 
and targeted therapies have been developed, the first ever cancer therapeutic, mustard 
gas, was discovered serendipitously in the 1940s during WWII
143
. Ever since, hundreds 
of chemotherapies are available today for treating cancers. These chemotherapies can be 
categorized in different classes of drugs based on their mode of action as seen in Table 
3
79
. While there are a myriad of chemotherapeutic agents, only some of these have 
become standard of care (SoC) chemotherapies based on their efficacy at treating 
cancers. Some SoC chemotherapies today are cisplatin, doxorubicin, gemcitabine, 5-FU 
and are used either as a monotherapy or a combination therapy with other anti-cancer 
drugs. It is important to note that not only do different types of cancer have various SoC 
treatments, but also different stages within the same cancer type can have different SoC 
treatment. This is based on extensive clinical evidence proving the safety, efficacy and 
potency of these chemotherapies. For example, the SoC for stage IV gastric cancer are 
eight chemotherapies therapies, one of which is a combination therapy with cisplatin and 
5-FU
80
. Whereas for NSCLC lung cancer, one of the SoC treatment is a combination of 
cisplatin and gemcitabine 
135
. 
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Table 3: Categories of different types of chemotherapies.* 
*Adapted from www.cancer.org
77 
Category of Chemotherapy Examples 
 
 
 
Alkylating Agents 
Nitrogen mustards: chlorambucil, mechlorethamine, 
cyclophosphamide 
Nitrosurea: streptozocin, carmustine (BCNU), and 
lomustine 
Alkyl sulfonates: busulfan 
Triazines: dacarbazine (DTIC) and temozolomide 
(Temodar
®
) 
Ethyleinmines: thiotepa and altretamine 
(hexamethylmelamine) 
Platinum drugs: cisplatin, carboplatin and oxoplatin 
 
 
 
Antimetabolites 
5-fluorouracil (5-FU),6-mercaptopurine (6-MP), 
Capecitabine (Xeloda®)Cladribine, Clofarabine, 
Cytarabine (Ara-C®)Floxuridine, Fludarabine, 
Gemcitabine (Gemzar®), Hydroxyurea, 
Methotrexate, Pemetrexed (Alimta®), Pentostatin, 
Thioguanine 
 
 
 
 
Anti-tumor Metabolites 
Anthracyclines: Daunorubicin, Doxorubicin 
(Adriamycin
®
), Epirubicin ,Idarubicin 
Non anthracyclines: Actinomycin-D, Bleomycin, 
Mitomycin-C 
 
 
Topoisomerase inhibitors 
Topoisomerase I inhibitors: topotecan and 
irinotecan (CPT-11). 
Topoisomerase II inhibitors: etoposide (VP-16), 
teniposide and Mitoxantrone 
 
 
 
 
Mitotic inhibitors 
Taxanes: paclitaxel (Taxol
®
) and docetaxel 
(Taxotere
®
) 
Epothilones: ixabepilone (Ixempra
®
) 
Vinca alkaloids: vinblastine (Velban
®
), vincristine 
(Oncovin
®
), and vinorelbine (Navelbine
®
) 
Estramustine (Emcyt
®
) 
 
Corticosteroids prednisone, methylprednisolone (Solumedrol
®
), and 
dexamethasone (Decadron
®
). 
 30 
Traditional chemotherapies have been effective at killing cancer cells by 
interfering with the cell division process
79
. However, while these drugs specifically target 
rapidly dividing cells, they are non-specific in that they don’t distinguish between cancer 
cells and rapidly diving cells of the body such as GI epithelium, skin and bone marrow
79
. 
As a result, they cause undesirable adverse effects to patients in the clinic. Moreover, 
over the course of the treatment, some cancer cells in the tumor develop resistance to 
these drugs and become unresponsive to chemotherapies
51
.
 
 This poses a major concern in 
the clinic and limits the use of these drugs. Thus, researchers are constantly investigating 
new drugs and therapeutics to overcome resistance and minimize toxicity. 
One way to overcome the problems mentioned above and effectively treat cancer 
is by the development and utilization of targeted therapies. Many signaling pathways are 
deregulated in cancer cells leading to their malignant phenotypes
82
. Targeted therapies 
are designed to selectively target molecular agents involved in cancer pathways. 
Several EGFR driven cancers such as that of the breast, lung, head and neck, and 
colon cancer have targeted therapies developed against different ErbB receptors and are 
used to treat associated cancers. These can be divided into different classes such as small 
molecule inhibitors and monocloncal antibodies (mAB)
83
.  
For instance, gefitinib and erlotinib are EGFR inhibitors and are used in first line 
treatment of advanced NSCLC with EFGR mutation that leads to activation of anti-
apoptotic Ras
83
. Gefitinib and erlotinib, both, have a similar mode of action and inhibit 
the tyrosine kinase domain of EGFR by binding to the ATP binding domain of the 
enzyme thereby inhibiting phosphorylation of the tyrosine domains of the receptor 
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(Figure 12). This in turn inhibits the anti-apoptotic signaling from the mutant receptor 
and causes cell death
83
.  These two inhibitors were significant more effective than 
treatment with traditional chemotherapies alone. For gefitinib, median progression free 
survival (PFS) of patients who received gefitinib versus those who received carboplatin 
plus paclitaxel was 10.8 months versus 5.4 months, respectively, which is a two-fold 
increase in PFS
84
. Similarly, erlotinib also showed 2x increase in the median PFS of 
patients versus patients given platinum based chemotherapy only. The median PFS was 
10.4 months in the erlotinib arm and 5.2 months in the platinum-based chemotherapy 
arm
85
. For HER2 driven cancers, especially, HER+ breast cancer, lapatinib, a small 
molecule inhibitor that inhibits the kinase activity of EGFR and HER2 simultaneously, 
has already been approved for treatment. Its mode of action is similar to that of erlotinib 
and gefitinib except it has dual action and blocks the ATP binding sites in EGFR and 
HER2 and inhibits receptor signaling
86
. In clinical setting, while lapatinib was found to 
be effective as a monotherapy, it has been found to be most effective when used in a 
combination therapy. In a phase III clinical trial, median PFS in the lapatinib plus 
capecitabine arm was 36.9 weeks as compared with 17.9 weeks in the capecitabine 
monotherapy arm
87
. Today, many other small molecules are under investigation in lab 
and the clinic. 
Cetuximab, a chimeric mAb against the extracellular ligand binding domain of 
EGFR (Figure 12), is used first line for treating metastatic colorectal cancer, metastatic 
NSCLC and head and neck cancer
88,89
. In clinical trials with two arms: one with 
Cetuximab in combination of FOLFIRI (irinotecan, 5-FU and leucovorin) and the other 
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with just FOLFIRI, PFS was significantly better in the former compared to the latter
90
. A 
second mAb in the clinic, Panitumumab, is a fully humanized monoclonal antibody 
against the extracellular ligand-binding domain of EGFR. This is used to treat metastatic 
colorectal cancer with disease progression on or following fluoropyrimidine-, oxaliplatin, 
and irinotecan-containing regimens and was found to benefit such patients in phase III 
trials
91
.  
 
Figure 12: EGFR inhibitors and their mode of action 
Cetuximab, mAb, binds to the extracellular domain of the EGFR receptors, while Erlotinib and Gefinitib, 
TKIs, bind to the tyrosine kinase domain.  
Taken from http://cancergrace.org/cancer-treatments/2008/03/21/egfr-combo-in-adv-nsclc/
90
. 
 
For treating metastatic HER2+ breast cancer, Herceptin, a fully humanized 
monocloncal antibody that targets the extracellular domain of HER2 was developed 
(Figure 13)
93
. It acts by blocking the HER2 signaling cascade as well as recruiting 
antibody-dependent cellular cytotoxicity
94,100
. Original studies by Hudis et al. showed 
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that trastuzamab improved the overall survival in metastatic HER2+ breast cancer 
patients from 20.3 to 25.1 months. In the trastuzumab for gastric cancer (ToGA) trial, 
patients were randomized into either a control arm with standard chemotherapy or in the 
treatment arm with standard chemotherapy plus trastuzumab. The results from this study 
found that the overall survival was much longer in the case of the treatment arm than in 
the control arm with a median overall survival of 13.8 month versus 11.1 months in the 
trastuzumab arm versus control arm respectively. As a result of these studies, 
trastuzumab is used as first-line treatment for HER+ breast cancer, as an adjuvant therapy 
in late stages of breast cancer
95
 and first line combination therapy for gastric cancer
100
. 
Another monoclonal antibody, Pertuzamab, is used to treat HER2+ breast cancer, 
however, in combination with trastuzamab and docetaxel
96
. This antibody is a HER2 
dimerization inhibitor. It binds to HER2 such that it inhibits dimerization of HER2 with 
other receptors and slows tumor growth (Figure 13)
97
. In the CLEOPATRA phase III 
clinical trial, the efficacy of combination of pertuzumab, trastuzamab and docetaxel 
compared to placebo, trastuzumab, and docetaxel in patients with HER2-positive first-
line metastatic breast cancer was evaluated. The former arm had a significantly prolonged 
PFS as compared with placebo, trastuzumab and docetaxel arm, when used as first-line 
treatment for HER2-positive metastatic breast cancer, with a PFS of 18.7 versus 12.4 
months, respectively
99
. 
A new class of drugs, antibody-drug conjugates, is being used to target specific 
cancers such as HER2+ breast cancer. TDM-1 is an antibody-drug conjugate comprising 
of trastuzumab conjugated to a cytotoxic agent called DM-1
138
. Trastuzumab inhibits the 
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growth of tumor cells by directly binding to HER2, while DM1 enters the cells and bind 
to tubulin, thereby, killing the cells
139
. Furthermore, in the EMILIA phase III clinical 
trial, TDM-1 proved to be superior in treating advanced stage metastatic breast cancer 
patients already resistant to trastuzumab. TDM-1 increased the mean PFS by 5.8 months 
when compared to the combination of lapatinib and capecitabine
139
. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: HER2 inhibitors and their mode of action 
Trastuzumab and pertuzumab both bind differently to the extracellular domain of HER2 and act under 
different conditions. Pertuzumab is effective at blocking ligand-dependent heterodimerization of HER2, 
while Trastuzumab is effective at blocking ligand-independent heterodimerization of HER2. Taken from 
Goltsov, A. et al 2014(113).  
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RESISTANCE TO TARGETED THERAPIES 
Although targeted therapies have exhibited significant therapeutic benefit over 
traditional chemotherapies, tumors eventually become resistant to these drugs as well. 
One case by Kobayashi et al. in 2005 reported an additional mutation in the EGFR 
receptor in specimens from patients with NSCLC who were responsive to gefitinib. This 
mutation was discovered after these patients relapsed after two years of complete 
remission post gefitinib treatment. The mutant EGFR, later called EGFR 790M, was 
found to cause resistance to gefitnib
101
. However, alternate mechanisms of resistance to 
gefitinib and erlotinib have also been found. One of them involves amplification of MET 
oncogene, which causes resistance by HER3-dependant activation of PI3K pathway
102
. 
This was confirmed in the same study by examining MET copy number in lung cancer 
specimens of patients that developed resistance to gefitinib or erlotinib
102
. Studies have 
proposed that lateral signaling occurs between ErbB receptors and that HER2 
overexpression due to EGFR TKI treatment may lead to resistance by lateral signaling 
and formation of HER2-HER3 heterodimers. As a result, these heterodimers would 
activate the PI3K signaling pathway and lead to resistance to TKIs
103
. Other in vitro and 
in vivo studies have implicated EGFR and HER2 in activating HER3 signaling and 
induced resistance in tumor cells post ligand activation of HER3
104,105,111
.  
TKIs against EGFR and HER2 have found to block the MAPK pathway, but very 
transiently block the PI3K pathway. This was attributed to continual activation of HER3, 
which potently activates PI3K. However, HER2 as a heterodimeric partner was found to 
be necessary for HER3 activation. Furthermore, the desensitization of HER3 signaling to 
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TKI was caused due to a forward shift in the HER3 phosphorylation-dephosphorylation 
equilibrium reactions and establishes a new steady stage for HER3 phosphorylation in 
spite of inhibition by TKIs. This forward shift leads to superphosphorylation of the HER3 
and Akt, which constantly activates the Akt pathways. This was confirmed by adding an 
irreversible HER family TKI that led to desensitization of HER3 activity even in the 
presence of the other drugs. 
Similarly, studies have found that trastuzumab associated resistance in HER2+ 
breast cancer can also be driven by HER3 upregulation and activation
106
. Trastuzumab 
blocks HER2 and HER3 when they are not dimerized. Since trastuzumab does not inhibit 
ligand induced HER2-HER3 heterodimer formation, resistance occurs via upregulation of 
HER3, which overcomes the effects of trastuzumab and activates the PI3K pathway
107,108
.  
HER3 upregulation has also been shown to provide tumors an escape mechanism from 
lapatinib therapy in not only preclinical models, but also in patients
114
. 
Additionally, studies have found HRG induced heterodimerization in NSCLC as 
an important resistance mechanism as well
109
. Finally another important consequence of 
HER3 overexpression and driven resistance is poor outcomes in a number of cancers. A 
meta-analysis performed by Ocana et al. showed that in a number of solid tumor studies, 
HER3 expression was shown to have worse survival outcomes in patients. One of the 
proposed mechanisms was attributed to HER3 induced resistance to therapeutics
110
. 
Since HER3 is a focal point for both, initial effectiveness of EGFR and HER2 
therapies as well as for tumor resistance, it has been of great interest as a pharmacological 
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target
112
. Several molecules against HER3 are currently in clinical development. 
However, since HER3 insignificant kinase activity, only mAb can be developed HER3.  
Some of the HER3 inhibitors that are currently under investigation can be found 
in Table 4. 
Table 4: ErbB3 inhibitors currently in development.*  
 *Table adapted from Jiang et al. 2012(119) 
**Phase II trial was discontinued in February 2015 
 
In preclinical as well as early clinical studies, HER3 inhibitors listed above have shown 
promising effects on tumors. For instance, MM-111 is a bispecific antibody with 
specificity and avidity to HER2 and HER3 expressing tumor cells (Figure 14). The HER2 
–binding arm of MM-111 acts as the docking arm and the therapeutic HER3 arm blocks 
HRG induced HER3 activity, thereby, inhibiting cell growth, proliferation and 
progression of cancer
115
.  
MM-121 is a fully humanized monoclonal antibody targeted against the ligand-
binding domain of HER3. Figure 15 below gives the mode of action of this antibody. 
MM-121 binds to the ligand binding domain of HER3 and (i) inhibits downstream 
DRUG TYPE TARGETS DEVELOPMENT 
PHASE 
SPONSOR 
MM-111 Bispecific 
Antibody 
HER2,HER3 Phase II** Merrimack 
Pharmaceuticals 
MM-121 
(seribantumab) 
Humanized 
mAb 
HER3 Phase II Merrimack 
Pharmaceuticals 
MM-141 Bispecific 
Antibody 
IGFR-1, 
HER3 
Phase I Merrimack 
Pharmaceuticals 
U3-1287 
(patritumab) 
Humanized 
mAb 
HER3 Phase III Daiichi Sankyo 
MEHD7945A mAb EGFR, 
HER3 
Phase II Genentech 
AZD8931 Pan 
inhibitor 
HER1/2/3 Phase I/II AstraZeneca 
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signaling of HER3 i.e. PI3K/Akt and MAPK pathway, (ii) receptor degradation by 
receptor internalization
120
. 
Figure 14: Mode of action of MM-111  
MM-111’s two arms, the docking HER2 arm is a high affinity arm and binds first, followed by the avidity 
due to which the therapeutic HER3 arm binds to HER3. This leads to inhibition of downstream signaling 
by preventing the binding of heregulin. Taken from Onsum, M et al. 2012(118). 
 
 
Figure 15: Mode of action of MM-121 
MM-121 binds to the ligand-binding domain of HER3 and prevents heterodimerization. This leads to (i) 
inhibition of signaling cascade and, (ii) degradation of the receptor by endocytosis. Taken from Onsum, M 
et al. 2012(118). 
 
Studies from MM-111 and MM-121 have led to a deeper understanding of their 
therapeutic potential and actions in humans. As mentioned earlier, mathematical 
modeling of the ErbB signaling pathway and sensitivity analysis of this model reveals 
HER3 as the most sensitive node for inhibiting the PI3K pathway. Further simulation 
analysis demonstrated two important findings: (1) an anti-HER3 antibody would be 
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potent in a low HER2 setting and, (ii) an HER2/HER3 bispecific molecule would be 
effective in a high HER2 setting. Figure 16 shows the results of computational 
simulations that led to these results. MM-121 and MM-111 were two molecules designed 
and developed that fit in the criteria determined by computational models. The results 
from the simulations were further confirmed by examining the effects of MM-111 and 
MM-121 in vitro in different cancer cell lines with a variation in their HER2 receptor 
levels as seen in Figure 17. It has been hypothesized that the potency of these inhibitors is 
affected by HER2 expression levels because of the fact that pre-formed HER2/HER3 
dimers have a much higher affinity for HRG and thus high HER2 levels decreases the 
potency of MM-121 due to large numbers of HER2/HER3 dimers. However, in order to 
counter the effects of pre-formed HER2/HER3 dimers in high HER2 setting, a bispecific 
molecule such as MM-111 would be much more potent than MM-121 due to avid binding 
of this molecule 
118,140
. 
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Figure 16: Stimulation of ErbB signaling network 
The curve above indicates that HER3 specific IgG is more effective in low HER2 settings while HER2/3  
bi-specific IgG is most effective in high HER2 settings. Taken from Onsum, M et al. 2012(118)
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Figure 17: Potency of MM-111 and MM-121 is determined by levels of HER2 
Potency of MM-111 and MM-121 related to HER2 expression on cells. Different cancerous cell lines with 
variable HER2 levels are shown above. MM-111 is most potent in a high HER2 setting while MM-121 is 
most potent in low HER2 setting. It is important to note that exogenous ligand, HRG stimulation was 
present in all experiments above as per computational stimulations. Taken from Onsum, M et al. 2012(118) 
 
Consequently, another important finding from the results discussed above was the 
identification of biomarkers in cancer cells to determine what molecule would be most 
effective in treating patients. For MM-111, after in vitro and in vivo validation, we now 
know that biomarkers positive patients are those that have high HER2, high HRG and 
HER3
141
. On the other hand, for MM-121 biomarker positive patients are those that have 
high HRG and low HER2
141
. 
In preclinical studies, MM-111 has proven to be a superior inhibitor of heregulin-
induced HER3 activation to lapatinib, pertuzumab and trastuzumab, which was at 
inhibiting ligand induced HER3 and AKT phosphorylation.  Moreover, MM-111 
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combines favorably with trastuzumab or lapatinib to inhibit growth of HER2-
overexpressing tumors in vivo. Additionally, MM-111 has been shown to re-sensitize 
HRG-HER3 induced paclitaxel resistant gastric cancer spheroid to paclitaxel as well as 
xenograft tumors in vivo. In addition to overcoming resistance in HER2+ gastric cancer 
models, MM-111 was shown to be synergistic with trastuzumab and paclitaxel in treating 
HER2+ xenograft tumors in vivo. These findings led to further clinical investigation of 
MM-111 in patients. Although MM-111 was proven to be safe and tolerable by patients 
in phase I studies, phase II trials investigating combination of MM-111 with trastuzumab 
and paclitaxel versus trastuzumab and paclitaxel in second line treatment of HER2+ 
gastric/gastroesophageal cancer, were discontinued due to shortage of PFS in the 
experimental arm compared to the control arm of the study
116, 117
. However, preliminary 
analysis of the study reveals that the patients enrolled in the study had HRG levels well 
below the threshold necessary for MM-111 to be therapeutic
117
. 
In preclinical studies, MM-121 potently prevented resistance to anti-EGFR 
therapies in vitro and in vivo
120
. Furthermore, the activity of MM-121 was assessed in 
genetically engineered mouse models of lung cancers driven by EGFR T790M-L858R. 
T790M mutation in EGFR causes cancer cells to be resistant to EGFR TKIs, gefitinib and 
erlotinib, and is seen in this animal model as well
101,122
.  Furthermore, this animal model 
exhibited resistance to cetuximab as a result of reactivation of HER3 and increase HRG 
expression. Adding MM-121 along with cetuximab inhibited the resistance and made the 
cancer cells sensitive to cetuximab
120
. Other preclinical studies have reported that 
combination of MM-121 with erlotinib completely inhibited Akt activation in pancreatic 
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cancer cells
123
. MM-121 also inhibited growth of ovarian cancer cells both in vitro and in 
vivo
124
. Gefitinib-resistant lung cancer cell lines were resensitized to gefitinib after being 
treated with MM-121
122
. 
As a result of these findings, currently there are 7 active clinical trials in phase I/II 
for MM-121 in combination with chemotherapies and other HER inhibitors for different 
cancer indications. While several phase II studies for MM-121 have been completed, 
some of them include two trials in breast cancer in combination with either paclitaxel or 
exemestane; one trial in ovarian cancer in combination with paclitaxel; and one trial in 
lung cancer in combination with erlotinib. In all of these studies, MM-121 showed a 
favorable effect in treating the cancer types in combination with other chemotherapies in 
patients with high heregulin. 
MM-141 is a bispecific tetravalent antibody that binds to IGR1-R and HER3 and 
behaves as a tetravalent inhibitor of the PI3K pathways associated with IGF-1R and 
HER3. This novel molecule was designed and developed using a systems biology 
approach and was proven to be superior to monoclonal antibody combinations to IGF-R1 
and HER3 in silico, in vitro and in vivo
142
. The rationale underlying the design of this 
molecule lies in the fact that many cancer cells respond to multiple growth factors and 
redundantly activate Akt. Thus in the case of MM-141, this molecule blocks PI3K 
signaling associated with IGF1, IGF2 and HRG by blocking their binding to IGF-R1 and 
HER3 receptively and induces receptor degradation
142
. Currently, the clinical activity and 
safety of MM-141 is under investigation in a phase I trial on patients with advanced solid 
tumors
125
. 
 44 
Another HER3-targeted drug is patritumab(U3-1287), the first fully humanized 
HER3 monoclonal antibody. Patritumab functions by inhibiting proximal and distal HER 
signaling and inducing rapid internalization of the receptor. In preclinical studies, 
patritumab showed inhibition of cancer growth in several in vivo cell lines such as those 
of the breast, lungs and colorectal. Furthermore, similar effects were seen in vivo in 
pancreatic, NSCLC and colorectal cancer xenograft models
127
. Currently, three phase I 
trials have been completed and they have shown that patritumab is well tolerated in 
NSCLC patients when combined with erlotinib; it was well tolerated in patients with 
advanced solid tumors and even showed evidence of disease stabilization in some 
cases
128
. A phase Ib/II trial using patritumab in combination with trastuzumab and 
paclitaxel is currently active with newly diagnosed metastatic breast cancer while a phase 
III trial is currently recruiting NSCLC patients to be treated with patritumab plus erlotinib 
or placebo plus erlotinib
129
. 
Aside from mAb, there are also antibodies developed that inhibits the 
dimerization of HER family receptors. Pertuzumab, discussed above, is one of those 
antibodies, which has proven to provide clinical benefit in HER2+ breast cancer patients. 
There are clinical trials going on to see the effects of pertuzumab in other cancer 
indications such as gastric cancer
130,131
. 
Another class of drugs called, pan inhibitors, are under development. One of the 
most advanced candidates is AZD8931, which is an equipotent, reversible inhibitor of 
EFGR, HER2, HER3. In vitro studies showed that AZD8931 is more potent than gefitinib 
or lapatinib in NSCLC and squamous cell carcinoma cell lines of the head and neck. 
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Furthermore, in vivo studies showed that ZD8931 inhibited xenograft growth in a range 
of models while significantly affecting EGFR, HER2, and HER3 phosphorylation and 
downstream signaling pathways, apoptosis, and proliferation
132
. Currently, a phase I trial 
is recruiting patients with esophageal cancer and gastro-esophageal cancer for 
combination treat of AZD8931 with oxaliplatin and capecitabine
133
. 
With these new and upcoming targeted therapies for HER3, researchers and 
clinicians are hopeful that more effective therapies for ErbB driven cancers will enter the 
clinic soon. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 46 
DISCUSSION 
For decades, research around the ErbB family of receptors has been limited to 
dysregulation of EGFR and HER2 in cancer. Preclinical and clinical evidence indicates 
that HER3 reactivation or HER3 induced resistance to therapeutics in cancer is a major 
concern. Only recently have scientists have understood the clinical significance of HER3 
and its role in cancer. Thus, while there are many potentially promising HER3 targeted 
drugs currently in clinical development, there is still an urgency and need to strategically 
develop new drugs in order to eliminate HER3 driven resistance and progression of 
cancer. 
Such advancements can be made by two ways: (i) Using the systems biology to 
determine the most effective molecule designs by understanding ErbB network biology 
(ii) Making strategic drug combinations to supplement standard chemotherapies regimens 
and targeted agents. 
Systems biology, as discussed earlier, is the computational and mathematical 
modeling of complex biological systems. By utilizing this holistic approach to biomedical 
research, Schoeberl et al. developed and trained a computational model to explore 
optimal ways to therapeutically inhibit combinatorial ligands that induce activation of 
ErbB/PI3K axis
120,124
. Further analysis found that HER3 was a critical node in PI3K/Akt 
pathway activation in cancer. The model further suggested that therapeutic intervention 
of this target might help cure cancer in patients. Based on this knowledge, MM-121 was 
developed and its action was consistent with that described by the computational model 
of binding to HER3, blocking HRG binding to HER3 and block BTC induced 
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phosphorylation of HER3
120,124
. Furthermore, these models helped determine the positive 
biomarkers that these drugs would be most therapeutically responsive. 
Similarly, McDonagh et al. extended the computational model of ErbB signaling 
previously developed by Schoeberl et al. to design an optimal molecule to inhibit ligand 
activated HER2/HER3 heterodimers in HER2 overexpressing tumors
115
. Simulations 
from the model predicted a bispecific antibody that would bind to HER2 and 
subsequently to HER3 and would block ligand induced receptor activation
115
. This 
proved to be highly effective and superior in treating HER2-amplified tumors over 
monospecific HER2/HER3 inhibitors,
 
which have been discussed in the previous 
section
115
.  
The studies discussed above confirm systems biology as a valid approach in 
designing and developing molecules. By understanding the network biology of ErbB 
receptors using systems biology, one can get a deeper insight into the interaction of how 
different ErbB monomers interact with one another and form all possible heterodimers. 
From this knowledge, potential molecules could be designed using systems biology that 
could block all the possible heterodimers of HER3 while simultaneously leading to 
receptor internalization as well as recruiting the immune system to attack targeted tumor 
cells.  
Merrimack Pharmaceutical is a development stage pharmaceutical company that 
develops drugs using a systems biology approach. In addition to MM-111 and MM-121, 
Merrimack has several other antibodies in its pipeline aimed towards treating ErbB 
resistance cancers. Using predictive models and computational analysis, Merrimack has 
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developed MM-141, a bispecific antibody that blocks HER3 and IGF-1R; MM-151 
which is a trimeric oligoclonal antibody that binds to three different epitopes on the 
EGFR receptor and MM-131 which is a bivalent anti-c-Met antibody that has a c-Met 
arm that competitively binds to c-Met receptor while the targeting arm binds to EpCAM, 
an tumor antigen
125
. In fact, Merrimack is using computational modeling to determine the 
optimal drug combinations in addition to its own drugs as well as the optimal dosage to 
effectively treat tumors. 
 Researchers and pharmaceutical companies should start adopting systems biology 
as a valid approach for finding and developing novel therapeutic targets for not only 
fighting tumor resistance, but also inhibiting cancer progression driven by HER3. 
Utilization of this strategic in silico approach would not only provide information for 
developing novel and effective molecules, but also expedite drugs to the clinic by 
overcoming the need of performing large chemical screens in the laboratory. 
A second way to make advancements in therapies for HER3 driven and HER3 
resistant tumors is by combining targeted therapies with traditional chemotherapies. 
While combination therapies have been around since the 1960s, when it was used first by 
James Holland, Emil Freireich and Emil Frei, strategic and rationally justified 
combination therapies should be developed to conquer drug resistance and enhance anti-
tumor activity of ErbB directed therapies
145
. Due to the relationship of HER3 signaling 
with sensitivity or resistance to HER-targeted therapy, HER3 may be considered a 
valuable biomarker to monitor the efficacy of HER-targeted therapy. Thus, for example, 
in HER2+ breast cancer treated with trastuzumab, the potential HER3-driven resistance 
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should be targeted with HER3 inhibitors in combination to trastuzumab. In other words, 
combination of HER3 and EGFR/HER2-targeted agents might be an effective way to 
overcome HER3 induced resistance and deliberate the sensitivity to HER-2 targeted 
drugs. This approach has already been validated and is currently used in the clinic for 
treating HER2+ breast cancer by combining trastuzumab and pertuzumab
144
. On the 
contrary, the phase III MARIANNE study in which combination of TDM-1 and 
pertuzumab was compared the standard of care combination of trastuzumab and taxanes 
in treating previously untreated HER2+ breast cancer, did not prove the TDM-1 plus 
pertuzumab arm to be superior over the trastuzumab plus taxane arm in spite of the 
combination of two HER2 targeted therapies in the experimental arm
148
. This study 
indicates that while in theory targeted combination therapies maybe seem effective, it is 
much more complicated than that. Another approach could be the combination of 
inhibitor of molecular targets downstream of HER3, such as PI3K/Akt inhibitors, in 
combination to other targeted drugs and chemotherapies. This might prove to enhance 
antitumor effects by blocking PI3K/Akt pathway which plays an important role in tumor 
progression and drug resistance. Moreover, reducing or blocking the release of ligands 
such as heregulin can also lead to HER3 inhibition and thus could be added to a 
combination therapy. 
   Furthermore, systems biology can play a major role in determining the most 
effective and optimal combination of targeted drugs and chemotherapies based on 
predictive models and outcomes. Using computational models one would be able to pick 
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the most optimal combinations, dosage and any temporal order of drug delivery to the 
tumor.  
Thus, systems biology as a field could prove to be a very effective approach for 
developing novel drugs for HER3 resistant and driven cancers as well as determining the 
most optimal combination therapies. Such combination therapies would include TKIs 
HER1/2, mAb against HER1/2/3, ligand blockers or antagonist and PI3K/Akt inhibitor in 
addition to standard chemotherapies that would hinder cell division. Finally, systems 
biology and computational modeling can be used to optimize the ideal dosage and 
temporal order of drug delivery, if needed. While in theory this may seem very idealistic, 
it is difficult to determine the toxicity of drugs without performing in vivo studies and 
clinical trials. Thus, further clinical evidence would be needed to validate the efficacy of 
systems biology in the clinic. 
FINAL CONCLUSION 
 
HER3 is a focal point in the ErbB family of receptors and plays a pivotal role in HER-
related cancer cell resistance as well as tumor progression. Thus, it is important to target 
HER3 to regain sensitivity to SoC drugs and treat cancer. Over the past decade, many 
HER3 inhibitors have been under investigation and have proven to be promising in 
preclinical studies. As more therapies against HER3 develop, adoption of strategic 
approaches, such as systems biology, are necessary to discover novel and effective 
molecules as well as to develop and optimize these molecules and use them in different 
combination therapies. One should also consider the synergistic potential of these drugs 
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in treating HER3 resistance cancers in combination to those already out there in the 
clinic. 
Thus, further research is needed to develop new or extend current computation models 
for ErbB networks in order to develop effective targeted drugs against HER3 with the aid 
of systems biology. 
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